Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antiviral drug resistance; Cytomegalovirus; Letermovir; Terminase

Indexed keywords

ALKALINE PHOSPHATASE; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; EXONUCLEASE; GW 275175X; LETERMOVIR; TERMINASE; TOMEGLOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME; VOLOCIXIMAB; 2-BROMO-5,6-DICHLORO-1-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; 3-HYDROXY-2,2-DIMETHYL-N-(4(((5-(DIMETHYLAMINO)-1-NAPHTHYL)SULFONYL)AMINO)PHENYL)PROPANAMIDE; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; DEOXYRIBONUCLEASE; NAPHTHALENESULFONIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE; RIBONUCLEOSIDE; UL56 PROTEIN, CYTOMEGALOVIRUS; UL89 PROTEIN, CYTOMEGALOVIRUS; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS RESISTANCE; EC50; GENE MUTATION; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIROGENESIS; WILD TYPE; CYTOMEGALOVIRUS; DRUG EFFECT; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; PATHOGENICITY;

ACETATES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; ENDODEOXYRIBONUCLEASES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHALENESULFONATES; QUINAZOLINES; RIBONUCLEOSIDES; VIRAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 85032432909     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01325-17     Document Type: Article

References (19)

1. Boeckh M, Geballe AP. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121:1673–1680. https://doi.org/10.1172/JCI45449.
2. Bogner E. 2010. Human cytomegalovirus packaging: an update on structure-function relationships. Future Virol 5:397–404. https://doi.org/10.2217/fvl.10.28.
3. Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, Biron KK, Boyd FL. 2004. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 48:1647–1651. https://doi.org/10.1128/AAC.48.5.1647-1651.2004.
4. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, Graeper S, Klenk HD, Ruebsamen-Waigmann H, Hallenberger S. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol 75:9077–9086. https://doi.org/10.1128/JVI.75.19.9077-9086.2001.
5. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2011. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 85: 10884–10893. https://doi.org/10.1128/JVI.05265-11.
6. Schleiss MR, Bernstein DI, McVoy MA, Stroup G, Bravo F, Creasy B, McGregor A, Henninger K, Hallenberger S. 2005. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res 65: 35–43. https://doi.org/10.1016/j.antiviral.2004.09.004.
7. Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Wester-man AC, Biron KK, Townsend LB, Drach JC. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 72:4721–4728.
8. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 72:717–725.
9. Chou S. 2015. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 59:6588–6593. https://doi.org/10.1128/AAC.01623-15.
10. Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2014. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother 58:610–613. https://doi.org/10.1128/AAC.01794-13.
11. Lischka P, Michel D, Zimmermann H. 2016. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK (8228). J Infect Dis 213:23–30. https://doi.org/10.1093/infdis/jiv352.
12. Nadal M, Mas PJ, Blanco AG, Arnan C, Sola M, Hart DJ, Coll M. 2010. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc Natl Acad Sci U S A 107:16078–16083. https://doi.org/10.1073/pnas.1007144107.
13. Yang J, Zhang Y. 2015. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43:W174–W181. https://doi.org/10.1093/nar/gkv342.
14. Champier G, Hantz S, Couvreux A, Stuppfler S, Mazeron MC, Bouaziz S, Denis F, Alain S. 2007. New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. Antivir Ther 12:217–232.
15. Wang Y, Mao L, Kankanala J, Wang Z, Geraghty RJ. 2017. Inhibition of human cytomegalovirus pUL89 terminase subunit blocks virus replication and genome cleavage. J Virol 91:e02152-16. https://doi.org/10.1128/JVI.02152-16.
16. Yan Z, Bryant KF, Gregory SM, Angelova M, Dreyfus DH, Zhao XZ, Coen DM, Burke TR, Jr., Knipe DM. 2014. HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses. mBio 5:e01318-14. https://doi.org/10.1128/mBio.01318-14.
17. Champier G, Couvreux A, Hantz S, Rametti A, Mazeron MC, Bouaziz S, Denis F, Alain S. 2008. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther 13:643–654.
18. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 54:1290–1297. https://doi.org/10.1128/AAC.01596-09.
19. Chou S, Ercolani RJ, Vanarsdall AL. 2017. Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene. J Clin Microbiol 55:2098–2104. https://doi.org/10.1128/JCM.00391-17.